Drug Information Association Logo

Meeting Programme


Connected Health is about more than the technology. It’s about being able to actively navigate holistically in an evolving healthcare ecosystem.

The DIA EuroMeeting allows you to debate the issues across the entire drug development value chain during the conference. You can also find solutions within the exhibition with 2500 other cross-functional thought leaders.

The EuroMeeting 2015 will give you the opportunity to share concepts with all the members of the healthcare value chain. No other conference and exhibition gathers such a comprehensive array of stakeholders.

You will be able to build relationships with those who shape your research & innovation (R&I), all the way through to the commercial & market access environment. This will allow you to streamline your response to dynamic market conditions and your ability to deliver your organisational objectives.



Download Brochure

  Download Registration Form      
   Download Advance Programme  



2015 EuroMeeting Themes and Theme Leaders as of 21 October 2014

Theme 1: New R&D models and innovative clinical trial methodologies. The role of the new clinical trials legislation
Susanna Del Signore, Associate Vice-President Global Regulatory Affairs, Head of Global Regulatory Policy, Sanofi R&D, France
Dorthe Poulsen, Chief Legal Adviser, EU-Coordinator, Danish Health and Medicines Authority, Denmark

Theme 2: Medical Devices and Combination Products
Paul Jansen, Global Head Medical Devices US, Sanofi, USA
Sabina Hoekstra-van den Bosch, Global Regulations and Standards, Philips Healthcare, the Netherlands

Theme 3: Advanced Therapies, Novel Treatments for Rare Diseases
Paula Salmikangas, Vice-Chair CAT, Senior Researcher, Finnish Medicines Agency (FIMEA), Finland
Henk Schuring, Group Vice President Regulatory Affairs - Europe, Genzyme Europe B.V., the Netherlands

Theme 4: Early Dialogue with Regulators and HTA Bodies on Innovative Medicines
Isabelle Clamou, Regulatory Affairs Director – EU Policy, Amgen, Belgium
Zaide Frias, Head of Regulatory Affairs and Best Evidence, Head of Human Medicines Research and Development Support (ad interim), European Medicines Agency, EU

Theme 5: Collaborative Consortia, IMI and the Way to Horizon 2020
Salah-Dine Chibout, Global Head Discovery & Investigative Safety, Global Head Preclinical Safety Therapeutic Areas, Novartis Pharma, Novartis Institutes for BioMedical Research, Switzerland
Fatiha Sadallah, Principal Scientific Manager, Innovative Medicines Initiative (IMI), Belgium

Theme 6: Implementing Innovation – Globally Conducive Regulatory Policies
Jun Kitara, International Liaison Officer, Pharmaceuticals and Medical Devices Agency (PMDA); networking Swissmedic, Switzerland
Henrik Kim Nielsen, Corporate Vice President, Regulatory Affairs Haemophilia, Novo Nordisk, Denmark

Theme 7: Special Development Pathways in Paediatrics, the Elderly and in Pregnancy
Sabine Atzor, Head of EU Regulatory Policies, F. Hoffmann-La Roche, Switzerland
Jordi Llinares, Head of Product Development Scientific Support, European Medicines Agency, EU

Theme 8: Translational Medicine and Regulatory Science
Anna CieĊ›lik, Director Department of Documentation Assessment, Office for Registration of Medicinal Products, Poland
Detlef Niese, Consultant, Dr. Niese Health Science and Policy, Germany

Theme 9 Big Data, Mobile Health   
Luca Pani, Director General, Italian Medicines Agency (AIFA), Italy
Duane Schulthess, Managing Director, Vital Tranformation, Belgium

Theme 10: Innovation in Vaccines Development
Richard Pisuldski, Vice President Global Regulatory Affairs, Sanofi Pasteur, France
Jan Willem van der Laan, Department of Pharmacology, Toxicology and Biotechnology (FTBB), Medicines Evaluation Board, Netherlands

Theme 11: Availability of Medicinal Products: Drug shortages
Belén Escribano Romero, Head of Department, Pharmaceutical Inspection and Enforcement Department, Spanish Medicines Agency (AEMPS), Spain
Pär Tellner, EFPIA ICH Coordinator, Director Regulatory Affairs, EFPIA, Belgium

Theme 12 Pharmacovigilance in 2015 - Poised for convergence of innovation
Maarten Lagendijk, Pharmacovigilance Coordinator, Medicines Evaluation Board (MEB), the Netherlands
Maria-Grazia Zurlo
, QPPV, Pfizer, Italy

Pre-conference Tutorials are being developed for Monday, 13 April 09:00 – 12:30.
Watch this web space for programme highlights and more details!
© 2015